Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).

被引：28

作者：

Richter, Joshua Ryan

Martin, Thomas G.

Vij, Ravi

Cole, Craig

Atanackovic, Djordje

Zonder, Jeffrey A.

Kaufman, Jonathan L.

Mikhael, Joseph

Bensinger, William

Dimopoulos, Meletios A.

Zimmerman, Todd M.

Lendvai, Nikoletta

Hari, Parameswaran

Ocio, Enrique M.

Gasparetto, Cristina

Kumar, Shaji

Oprea, Corina

Charpentier, Eric

Strickland, Stephen Anthony

Miguel, Jesus San

机构：

[1] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Washington Univ, St Louis, MO 63110 USA

[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[5] Huntsman Canc Inst, Salt Lake City, UT USA

[6] Karmanos Canc Inst, Detroit, MI USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] Mayo Clin, Scottsdale, AZ USA

[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[10] Univ Athens, Athens, Greece

[11] Univ Chicago, Chicago, IL 60637 USA

[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[13] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[14] Univ Hosp Salamanca, Salamanca, Spain

[15] Duke Univ, Med Ctr, Durham, NC USA

[16] Mayo Clin, Rochester, MN USA

[17] Sanofi Oncol, Cambridge, MA USA

[18] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[19] Univ Navarra, Pamplona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.8005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8005

引用

页数：2